<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2246">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131919</url>
  </required_header>
  <id_info>
    <org_study_id>N21PMA</org_study_id>
    <nct_id>NCT05131919</nct_id>
  </id_info>
  <brief_title>Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers</brief_title>
  <acronym>PUMA</acronym>
  <official_title>Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers. The PUMA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the efficacy of pembrolizumab in patients with locally advanced, irresectable&#xD;
      dMMR colorectal cancer will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this single-center, single arm, open-label, phase II study assessing the efficacy of&#xD;
      pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancer, 25&#xD;
      patients will be enrolled. All patients will be treated with pembrolizumab 200 mg&#xD;
      intravenously on day 1 of each 3-week cycle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm, open-label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancers by objective response rate (ORR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>ORR according to RECIST 1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the major pathological response (MPR) in patients undergoing surgery</measure>
    <time_frame>2.5 years</time_frame>
    <description>MPR is defined as &lt; 10% residual viable tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To find biomarkers and evaluation strategies able to accurately assess complete and near-complete responses in order to pursue organ-sparing treatment</measure>
    <time_frame>2.5 years</time_frame>
    <description>Association between changes in circulating tumor (ct)DNA and complete and near-complete responses, and risk of relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In case of surgery, to assess post-surgical outcome and infectious complications following neoadjuvant immunotherapy</measure>
    <time_frame>2.5 years</time_frame>
    <description>Post-surgical outcome will be assessed by pathologic evaluation, infection complications will be graded according to CTCAE V5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the date of relapse</measure>
    <time_frame>2.5 years</time_frame>
    <description>As determined by disease recurrence or disease-related death during follow-up after surgery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with pembrolizumab 200 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Treatment with pembrolizumab 200 mg intravenously on day 1 of each 3-week cycle. Treatment will be continued for a maximum duration of 2 years, or until the tumor becomes resectable.</description>
    <arm_group_label>pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Patients at least 18 years of age&#xD;
&#xD;
          -  Locally advanced, irresectable adenocarcinoma of the colon or rectum, not amenable to&#xD;
             surgery, or for which induction therapy is required to reconsider surgery, or where&#xD;
             free margins can only be obtained by major extension of the surgical procedure, as&#xD;
             defined by one of the following:&#xD;
&#xD;
               -  Invasion of the duodenum, stomach, spleen or pancreatic head, for which major&#xD;
                  extension of the surgical procedure would be required to obtain free margins,&#xD;
                  and/or for which the chances of positive resection margins are high&#xD;
&#xD;
               -  Invasion or encasement of major blood vessels (superior mesenteric vessels, iliac&#xD;
                  vessels, portal vein)&#xD;
&#xD;
               -  Invasion or encasement of the ureter&#xD;
&#xD;
          -  No signs of distant metastases on CT-scan and physical examination; patients may not&#xD;
             be eligible for first-line treatment with pembrolizumab according to SoC&#xD;
&#xD;
          -  Patients may not be eligible for standard of care first-line pembrolizumab for&#xD;
             metastatic disease&#xD;
&#xD;
          -  Patients may not be potentially eligible for the NICHE study: patients with primarily&#xD;
             resectable disease, for which relatively minor extension of the procedure is required&#xD;
             to achieve free margins, such as but not limited to a small bowel segment, abdominal&#xD;
             wall&#xD;
&#xD;
          -  ECOG performance status of 0 or 1. Evaluation of ECOG is to be performed within 7 days&#xD;
             prior to the first dose of study intervention&#xD;
&#xD;
          -  Screening laboratory tests must meet the criteria as defined in Table 1 and should be&#xD;
             obtained within 10 days prior to the start of study intervention:&#xD;
&#xD;
        Absolute neutrophil count (ANC) ≥1500/µL; Platelets ≥100 000/µL; Hemoglobin ≥9.0 g/dL or&#xD;
        ≥5.6 mmol/L, Creatinine OR Measured or calculated creatinine clearance (GFR can also be&#xD;
        used in place of creatinine or CrCl) ≤1.5 × ULN OR ≥30 mL/min for participant with&#xD;
        creatinine levels &gt;1.5 × institutional ULN; Total bilirubin ≤1.5 ×ULN OR direct bilirubin&#xD;
        ≤ULN for participants with total bilirubin levels &gt;1.5 × ULN; AST (SGOT) and ALT (SGPT)&#xD;
        ≤2.5 × ULN; International normalized ratio (INR) OR prothrombin time (PT) ≤1.5 × ULN unless&#xD;
        participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic&#xD;
        range of intended use of anticoagulants; Activated partial thromboplastin time (aPTT) ≤1.5&#xD;
        × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within&#xD;
        therapeutic range of intended use of anticoagulants&#xD;
&#xD;
          -  A male participant must agree to use a contraception as detailed in Appendix 2 of this&#xD;
             protocol during the treatment period and for at least 200 days (90 days plus the time&#xD;
             required for pembrolizumab to undergo five half-lives) after the last dose of study&#xD;
             treatment and refrain from donating sperm during this period.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to&#xD;
             registration (see appendix 2). If the urine test is positive or cannot be confirmed as&#xD;
             negative, a serum pregnancy test will be required&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant (see appendix&#xD;
             2), not breastfeeding, and at least one of the following conditions applies:&#xD;
&#xD;
               -  Not a woman of childbearing potential (WOCBP) as defined in appendix 2 OR&#xD;
&#xD;
               -  A WOCBP who agrees to follow the contraceptive guidance in appendix 2 during the&#xD;
                  treatment period and for at least 120 days (30 days plus the time required for&#xD;
                  pembrolizumab to undergo five half lives) after the last dose of study treatment.&#xD;
&#xD;
          -  CT-scan must be performed within 28 days prior to registration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No previous treatment with immune checkpoint inhibitors targeting including but not&#xD;
             limited to CTLA-4, PD-1 or PD-L1&#xD;
&#xD;
          -  No previous treatment with chemotherapy for the disease under study&#xD;
&#xD;
          -  No prior radiotherapy for the disease under study&#xD;
&#xD;
          -  No prior radiotherapy for other indications than the disease under study within 2&#xD;
             weeks of start of study intervention. Participants must have recovered from al&#xD;
             radiation-related toxicities, not require corticosteroids, and not have had radiation&#xD;
             pneumonitis.&#xD;
&#xD;
          -  No history of (non-infectious) pneumonitis/interstitial lung disease that required&#xD;
             steroids or has current pneumonitis/interstitial lung disease&#xD;
&#xD;
          -  Allergies and Adverse Drug Reaction&#xD;
&#xD;
               -  No history of allergy to study drug components&#xD;
&#xD;
               -  No history of severe hypersensitivity reaction to any monoclonal antibody&#xD;
&#xD;
          -  No intercurrent illnesses, including but not limited to infections, unstable angina&#xD;
             pectoris&#xD;
&#xD;
          -  No known history of Human Immunodeficiency Virus (HIV) infection and no known history&#xD;
             of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known&#xD;
             active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection.&#xD;
&#xD;
          -  No underlying medical conditions that, in the investigator's opinion, will make the&#xD;
             administration of the study drug hazardous or obscure the interpretation of toxicity&#xD;
             determination of adverse events&#xD;
&#xD;
          -  No active autoimmune disease requiring systemic treatment in the past 2 years;, or&#xD;
             other medical conditions requiring systemic steroid or immunosuppressive medications,&#xD;
             Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment and is allowed.&#xD;
&#xD;
          -  No diagnosis of immunodeficiency or conditions requiring systemic treatment with&#xD;
             either corticosteroids (&gt; 10 mg daily prednisone equivalents) or other&#xD;
             immunosuppressive medications within 14 days of study drug administration. Inhaled or&#xD;
             topical steroids and adrenal replacement doses &gt; 10 mg daily prednisone equivalents&#xD;
             are permitted in the absence of active autoimmune disease&#xD;
&#xD;
          -  No live vaccines in the 4 weeks prior to inclusion&#xD;
&#xD;
          -  No history of uncontrolled medical or psychiatric illness&#xD;
&#xD;
          -  No psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  No current pregnancy or breastfeeding&#xD;
&#xD;
          -  No active malignancies other than disease under study within 3 years prior to&#xD;
             inclusion, except for malignancies with a negligible recurrence rate (e.g. &lt;10% in 5&#xD;
             years)&#xD;
&#xD;
          -  No allogenic tissue/solid organ transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myriam Chalabi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruud Weijer, PhD</last_name>
    <phone>+31205129111</phone>
    <email>r.weijer@nki.nl</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 2, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

